Recapping the 2025 J.P. Morgan Healthcare Conference
This year’s edition of the annual J.P. Morgan Healthcare Conference has come to a close, with attendees enjoying sunny skies and a heavy police presence throughout the San Francisco-set event.
In this week’s episode of The Top Line, Fierce Pharma’s Zoey Becker and Angus Liu join Fierce Biotech’s …
A closer look at pharma's top R&D budgets
In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent special report from Fierce Biotech, ranking the top 10 R&D budgets from 2024.
Did Merck hold on to its 2023 crown? And did any new faces crack this year’s list? Listen to …
Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview
Despite the long holiday weekend, news in biopharma never slows down.
In this week’s episode of "The Top Line," the Fierce team breaks down some of the biggest stories from the past week.
On the pharma side, Eric Sagonowsky and Kevin Dunleavy examine Big Pharma’s first-quarter 2025 performance. W…
Biotech Graveyard
Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink.
In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came together to chat about themes from this year’s graveyard, including a cell therapy mausoleum, som…
The top 10 pharma R&D budgets of 2025
The wait is over. Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which companies are spending the most on innovation and how those investments are shifting year over year.
In this week’s episode of "The Top Line," Darren Incorvaia a…
Roivant’s CEO thinks China is a ‘red herring’
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline, the country is nothing more than a red herring.
In this week’s episode of "The Top Line," Fierce Biotech’s Darren Incorvaia chats with Gline about…
Boston, China and the future of biotech
Boston remains biotech's most influential hub, but the questions facing the region are increasingly global.
Recorded live at Fierce Biotech Week in Boston, this panel discussion brings together Uli Stilz, senior advisor at Flagship Pioneering; Bruce Beutel, CEO and co-founder of PassKey; and Ben B…
Behind the headlines of ASCO 2026
Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s annual meeting for a weekend of buzzy data drops, practice-changing posters and insightful sessions.
In this week’s episode of "The Top Line," Fierce Biotech and Fierce Pharma’s D…
5 emerging biotech hubs
Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead?
In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia and Will Maddox discuss a…
The future of RAS inhibitors
Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs.
In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorva…
محرك بحث البودكاست
يمكنك استخدام موقعنا الإلكتروني للبحث في ملفات podcast3,828,983وحلقات196,532,870حسب الأشخاص أو الأماكن أو المواضيع.
الاستثمار في المعرفة يحقق أفضل عائد، ولذلك أستمع إلى البودكاست.
‐ Benjamin "Llamacorn" Franklin
تعديل
شكراً على مساعدتنا في الحفاظ على قاعدة بيانات البودكاست مُحدَّثة.
